Immunome

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It focuses on oncology and infectious disease areas. It utilizes the proprietary human memory B cell platform to enable the discovery of novel antibodies in both these therapeutic areas because of the interrogation of memory B cells from patients who have learned to fight off these diseases. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the Omicron variant (BA.1) of SARS-CoV-2 when tested in vivo in hamsters. Additional in vitro testing of a SARS-CoV-2 pseudovirus also showed that IMM20253, one of the antibodies in I

Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “We received FDA clearance to proceed with our Phase 1b clinical trial for our three-antibody cocktail, IMM-BCP-01, for the treatment of COVID-19 and patient recruitment efforts are underway. B

Immunome Reports First Quarter 2022 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter ended December 31, 2021 and provided a corporate update. “There remains a clear need for safe and efficacious antibody treatments against COVID-19, especially those less susceptible to mutational drift. We believe our three-antibody cocktail, IMM

Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.

Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of SARS-CoV-2 (COVID-19). Immunome previously announced that the FDA had placed the company's IND app

FDA Lifts Clinical Hold on Immunome's IMM-BCP-01 IND Application for the Treatment of COVID-19

The FDA has lifted the clinical hold on Immunome Inc's (NASDAQ: IMNM) Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) to treat COVID-19.  Immunome previously announced that the FDA had placed its IND application on clinical hold.

FDA Lifts Clinical Hold on Immunome's COVID-19 Candidate IND

Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of the COVID-19 omicron variant. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced in vitro data demonstrating effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories (Boston University's National Emerging Infectious Diseases Laboratories and Washington University1). “We are p

Immunome's Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing

The stock price of Immunome, Inc. (Nasdaq: IMNM) fell by over 15% pre-market today. This is why it happened.

Immunome Stock (IMNM): Why The Price Noticeably Dropped Today

Immunome Inc (NASDAQ: IMNM) has received an FDA clinical hold letter in response to its recently submitted IND requesting further information related to the preparation and administration of IMM-BCP-01 at clinical sites. The Company has already initiated the requisite work and expects to provide the requested information quickly.

FDA Issues Clinical Hold On Immunome's COVID-19 Antibody Program

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced an update regarding its Investigational New Drug (IND) submission for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19). The Company received a clinical hold letter from the U.S. Food and Drug Administration (FDA) in response to its recently submitted IN

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that members of management will participate in a fireside chat hosted by Cantor Fitzgerald Analyst Brian Cheng on Wednesday, December 8, 2021 at 1:00 p.m. ET. The live call is reserved for institutional clients of Cantor Fitzgerald. A replay of the webcast can be accessed from the Inve

Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon mapping of those mutations and activity against previous and current CDC variants of concern, Immunome expects its antibody cocktail, IMM-BCP-01, to neutralize t

Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant

The stock price of Immunome Inc (NASDAQ: IMNM) increased by 12.55% in the most recent trading session. This is why it happened.

Immunome (IMNM) Stock: Why The Price Increased

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2 (COVID-19). “I am thrilled that Immunome has submitted its first IND, which is another milestone

Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2021 Financial Results

Immunome Reports Third Quarter 2021 Financial Results

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Stifel Healthcare Conference

Immunome to Present at the Stifel Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome Submits for Publication Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis

Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis

EXTON, Pa.--(BUSINESS WIRE)--Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at AACR NCI-EORTC Conference on Cancer Therapeutics

Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present Preclinical Data on Anti IL-38 at AACR's NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Cantor Global Healthcare Conference

Immunome to Present at the Cantor Global Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Immunome Inc's (NASDAQ: IMNM) three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against SARS-CoV-2 Lambda (C.37) and Delta AY.1/2 (Delta Plus) variants in preclinical testing.  Related Content:   Immunome's COVID-19 Antibody Shows Neutralizing Activity Against Delta Variant.

Immunome's COVID-19 Antibody Neutralizes Two Variant Strains In Animal Studies

EXTON, Pa.--(BUSINESS WIRE)--Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Second Quarter 2021 Financial Results

News for Immunome Stock (IMNM)